Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Takayasu Arteritis | 4 | 2018 | 6 | 0.710 |
Why?
|
Vascular Surgical Procedures | 1 | 2018 | 7 | 0.610 |
Why?
|
Tertiary Care Centers | 1 | 2018 | 80 | 0.580 |
Why?
|
Kidney Transplantation | 2 | 2014 | 42 | 0.480 |
Why?
|
Kidney Diseases | 3 | 2017 | 38 | 0.470 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 27 | 0.450 |
Why?
|
Child | 15 | 2018 | 2242 | 0.390 |
Why?
|
HIV Seropositivity | 1 | 2014 | 265 | 0.380 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2007 | 1 | 0.290 |
Why?
|
Palate, Hard | 1 | 2007 | 1 | 0.290 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2007 | 195 | 0.250 |
Why?
|
Glomerulosclerosis, Focal Segmental | 3 | 1999 | 5 | 0.220 |
Why?
|
Humans | 20 | 2018 | 14537 | 0.210 |
Why?
|
Nephrosis, Lipoid | 2 | 1998 | 2 | 0.180 |
Why?
|
Child, Preschool | 14 | 2017 | 1748 | 0.170 |
Why?
|
Female | 13 | 2018 | 9103 | 0.160 |
Why?
|
Angiography | 1 | 2018 | 6 | 0.150 |
Why?
|
Africa, Southern | 1 | 2018 | 91 | 0.150 |
Why?
|
Survival Rate | 1 | 2018 | 96 | 0.150 |
Why?
|
alpha 1-Antitrypsin | 1 | 1998 | 6 | 0.150 |
Why?
|
Retrospective Studies | 4 | 2018 | 799 | 0.150 |
Why?
|
Immunocompromised Host | 1 | 2017 | 34 | 0.140 |
Why?
|
Emphysema | 1 | 2016 | 2 | 0.140 |
Why?
|
Pyelonephritis | 1 | 2016 | 2 | 0.140 |
Why?
|
Immunogenicity, Vaccine | 1 | 2017 | 103 | 0.140 |
Why?
|
Male | 10 | 2018 | 6754 | 0.130 |
Why?
|
Nephrotic Syndrome | 3 | 1993 | 5 | 0.130 |
Why?
|
Treatment Outcome | 2 | 2018 | 889 | 0.130 |
Why?
|
Incidence | 1 | 2018 | 685 | 0.130 |
Why?
|
HIV Infections | 2 | 2017 | 5097 | 0.130 |
Why?
|
Pneumococcal Infections | 2 | 2017 | 299 | 0.130 |
Why?
|
HIV-1 | 2 | 2014 | 1260 | 0.120 |
Why?
|
Streptococcus pneumoniae | 2 | 2017 | 336 | 0.120 |
Why?
|
Pneumococcal Vaccines | 1 | 2017 | 278 | 0.110 |
Why?
|
Adolescent | 7 | 2013 | 2985 | 0.110 |
Why?
|
Infant Nutrition Disorders | 1 | 1992 | 4 | 0.100 |
Why?
|
Child Nutrition Disorders | 1 | 1992 | 13 | 0.100 |
Why?
|
Urinary Tract Infections | 1 | 1992 | 12 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2014 | 472 | 0.090 |
Why?
|
Tuberculosis, Pulmonary | 1 | 1993 | 324 | 0.090 |
Why?
|
Viral Load | 1 | 2014 | 819 | 0.090 |
Why?
|
Infant | 7 | 2017 | 2244 | 0.080 |
Why?
|
Mycobacterium avium Complex | 1 | 2007 | 2 | 0.070 |
Why?
|
Bone Marrow | 1 | 2007 | 19 | 0.070 |
Why?
|
Polyarteritis Nodosa | 1 | 2005 | 2 | 0.060 |
Why?
|
Periosteum | 1 | 2005 | 2 | 0.060 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2005 | 35 | 0.060 |
Why?
|
HIV | 1 | 2007 | 380 | 0.060 |
Why?
|
Anti-HIV Agents | 1 | 2013 | 1324 | 0.060 |
Why?
|
Alkylating Agents | 1 | 1999 | 1 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 1999 | 5 | 0.040 |
Why?
|
Radiography | 2 | 2005 | 80 | 0.040 |
Why?
|
South Africa | 6 | 2005 | 7596 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 1999 | 39 | 0.040 |
Why?
|
Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
Gene Frequency | 1 | 1998 | 122 | 0.040 |
Why?
|
Lung Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2017 | 42 | 0.040 |
Why?
|
Radiography, Abdominal | 1 | 2016 | 2 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2016 | 21 | 0.030 |
Why?
|
Immunization, Secondary | 1 | 2017 | 72 | 0.030 |
Why?
|
Genetic Variation | 1 | 1998 | 175 | 0.030 |
Why?
|
Serogroup | 1 | 2017 | 150 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 61 | 0.030 |
Why?
|
Kidney | 1 | 2016 | 46 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2017 | 153 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2017 | 231 | 0.030 |
Why?
|
Gallium Radioisotopes | 1 | 1994 | 2 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 1994 | 2 | 0.030 |
Why?
|
Lymphoid Tissue | 1 | 1994 | 7 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 1993 | 12 | 0.030 |
Why?
|
Body Weight | 1 | 1992 | 111 | 0.020 |
Why?
|
Hepatitis, Viral, Human | 1 | 1991 | 3 | 0.020 |
Why?
|
Nutritional Status | 1 | 1992 | 76 | 0.020 |
Why?
|
Hepatitis B | 2 | 1991 | 125 | 0.020 |
Why?
|
Prevalence | 1 | 1993 | 1192 | 0.020 |
Why?
|
Prospective Studies | 1 | 1992 | 1160 | 0.020 |
Why?
|
Glomerulonephritis | 1 | 1988 | 7 | 0.020 |
Why?
|
Antigens, Viral | 1 | 1988 | 21 | 0.020 |
Why?
|
Peritonitis | 1 | 1987 | 5 | 0.020 |
Why?
|
Penicillin Resistance | 1 | 1987 | 17 | 0.020 |
Why?
|
Measles | 1 | 1988 | 36 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 1988 | 111 | 0.020 |
Why?
|
DNA, Viral | 1 | 1988 | 165 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 1998 | 25 | 0.020 |
Why?
|
Hypertension | 1 | 1991 | 419 | 0.020 |
Why?
|
Fibula | 1 | 2005 | 4 | 0.020 |
Why?
|
Tibia | 1 | 2005 | 14 | 0.020 |
Why?
|
Leg | 1 | 2005 | 21 | 0.020 |
Why?
|
Hepatitis B virus | 1 | 1988 | 157 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 1999 | 11 | 0.010 |
Why?
|
Steroids | 1 | 1999 | 14 | 0.010 |
Why?
|
Drug Resistance | 1 | 1999 | 35 | 0.010 |
Why?
|
Age of Onset | 1 | 1999 | 32 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1998 | 4 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1994 | 2 | 0.010 |
Why?
|
Hypertension, Renovascular | 1 | 1994 | 4 | 0.010 |
Why?
|
Graft Survival | 1 | 1994 | 40 | 0.010 |
Why?
|
Hepatitis A | 1 | 1991 | 2 | 0.010 |
Why?
|
Hypertension, Renal | 1 | 1991 | 2 | 0.010 |
Why?
|
Acute Disease | 1 | 1991 | 105 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1988 | 6 | 0.000 |
Why?
|
Hepatitis D | 1 | 1988 | 4 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1988 | 63 | 0.000 |
Why?
|
Hepatitis B Surface Antigens | 1 | 1988 | 48 | 0.000 |
Why?
|
Hepatitis B e Antigens | 1 | 1988 | 26 | 0.000 |
Why?
|
African Americans | 1 | 1988 | 47 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1987 | 1479 | 0.000 |
Why?
|
Adult | 1 | 1991 | 5913 | 0.000 |
Why?
|